A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: Evaluation in a porcine model

被引:46
作者
Bhargava, B
Reddy, NK
Karthikeyan, G
Raju, R
Mishra, S
Singh, S
Waksman, R
Virmani, R
Somaraju, B
机构
[1] Washington Hosp Ctr, Washington, DC 20010 USA
[2] All India Inst Med Sci, New Delhi, India
[3] CARE Hosp, Hyderabad, Andhra Pradesh, India
[4] Inst Pathol, Gaithersburg, MD USA
关键词
drug-eluting stent; restenosis; polymer;
D O I
10.1002/ccd.20698
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: We aimed to evaluate the response of porcine coronary arteries to a novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt chromium stent. Background: Polymer based drug-eluting stents significantly reduce restenosis. However, the indefinite presence of polymer is thought to initiate and sustain inflammation and contribute to the occurrence of late complications. Methods: Sixteen carbon-carbon coated, nonpolymeric cobalt chromium stents with two different doses of paclitaxel (eight of each) were implanted in porcine coronary arteries. In addition, eight cobalt chromium stents coated with a biodegradable polymer were also studied. Animals were sacrificed 6 weeks after stent implantation and histomorphometric analysis was performed. Results were compared among the three groups of stents. Results: The cobalt chromium stents coated with carbon-carbon with low and medium doses of paclitaxel both showed acceptable performance characteristics, with respect to endothelialization, neointimal hyperplasia, percentage diameter stenosis, inflammatory response, and tendency to fibrin deposition, when compared to historical data with the Cypher stent. On the other hand, the stents coated with poly(lactide) and poly(lactide-co-glycolide) biodegradable polymers and 0.7 mu g/mm(2) paclitaxel showed poor performance. There was a significant tendency to poor endothelialization, greater neointimal hyperplasia, percentage diameter stenosis, greater inflammatory response, and tendency to fibrin deposition (P < 0.01 for all parameters). Conclusions: This preclinical evaluation demonstrates the safety and efficacy of a novel cobalt chromium stent with a carbon-carbon coating and low and medium doses of paclitaxel. (C) 2006 Wiley-Liss, Inc.
引用
收藏
页码:698 / 702
页数:5
相关论文
共 13 条
[1]   A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents [J].
Babapulle, MN ;
Joseph, L ;
Bélisle, P ;
Brophy, JM ;
Eisenberg, MJ .
LANCET, 2004, 364 (9434) :583-591
[2]   BIOCOMPATIBILITY OF POLYMER-COATED OVERSIZED METALLIC STENTS IMPLANTED IN NORMAL PORCINE CORONARY-ARTERIES [J].
DESCHEERDER, IK ;
WILCZEK, KL ;
VERBEKEN, EV ;
VANDORPE, J ;
LAN, PN ;
SCHACHT, E ;
DEGEEST, H ;
PIESSENS, J .
ATHEROSCLEROSIS, 1995, 114 (01) :105-114
[3]   Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents -: Three-year results of the RAVEL trial [J].
Fajadet, J ;
Morice, MC ;
Bode, C ;
Barragan, P ;
Serruys, PW ;
Wijns, W ;
Constantini, CR ;
Guermonprez, JL ;
Eltchaninoff, H ;
Blanchard, D ;
Bartorelli, A ;
Laarman, GJ ;
Perin, MA ;
Sousa, JE ;
Schuler, G ;
Molnar, F ;
Guagliumi, G ;
Colombo, A ;
Hayashi, EB ;
Wülfert, E .
CIRCULATION, 2005, 111 (08) :1040-1044
[4]   Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent - The European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial [J].
Gershlick, A ;
De Scheerder, I ;
Chevalier, B ;
Stephens-Lloyd, A ;
Camenzind, E ;
Vrints, C ;
Reifart, N ;
Missault, L ;
Goy, JJ ;
Brinker, JA ;
Raizner, AE ;
Urban, P ;
Heldman, AW .
CIRCULATION, 2004, 109 (04) :487-493
[5]   Platelet deposition on stainless steel, spiral, and braided polylactide stents - A comparative study [J].
Hietala, EM ;
Maasilta, P ;
Juuti, H ;
Nuutinen, JP ;
Harjula, ALJ ;
Salminen, US ;
Lassila, R .
THROMBOSIS AND HAEMOSTASIS, 2004, 92 (06) :1394-1401
[6]   Comparison of neointimal formation in polymer-free Paclitaxel stents versus stainless stents (from the ASPECT and ELUTES randomized clinical trials) [J].
Kaluza, GL ;
Gershlick, AH ;
Park, SJ ;
De Scheerder, I ;
Chevalier, B ;
Camenzind, E ;
Goy, JJ ;
Missault, L ;
Reifart, N ;
Vrints, C ;
Urban, P ;
Shim, WH ;
Ho, DSW ;
Fearnot, NE ;
Voorhees, WD ;
Raizner, AE .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (02) :199-201
[7]   Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy [J].
McFadden, EP ;
Stabile, E ;
Regar, E ;
Cheneau, E ;
Ong, ATL ;
Kinnaird, T ;
Suddath, WO ;
Weissman, NJ ;
Torguson, R ;
Kent, KM ;
Pichard, AD ;
Satler, LF ;
Waksman, R ;
Serruys, PW .
LANCET, 2004, 364 (9444) :1519-1521
[8]  
Schaub RD, 2000, J BIOMED MATER RES, V49, P460, DOI 10.1002/(SICI)1097-4636(20000315)49:4<460::AID-JBM4>3.0.CO
[9]  
2-3
[10]   Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent should we be cautious? [J].
Virmani, R ;
Guagliumi, G ;
Farb, A ;
Musumeci, G ;
Grieco, N ;
Motta, T ;
Mihalcsik, L ;
Tespili, M ;
Valsecchi, O ;
Kolodgie, FD .
CIRCULATION, 2004, 109 (06) :701-705